{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:09:51Z","timestamp":1793196591573,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s40265-025-02193-x","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T08:37:50Z","timestamp":1747643870000},"page":"945-955","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Vonoprazan: A Review in Erosive Esophagitis and Non-Erosive Gastro-Esophageal Reflux Disease"],"prefix":"10.1007","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0789-7765","authenticated-orcid":false,"given":"Simon","family":"Fung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"issue":"1","key":"2193_CR1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.14309\/ajg.0000000000001538","volume":"117","author":"PO Katz","year":"2022","unstructured":"Katz PO, Dunbar KB, Schnoll-Sussman FH, et al. ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2022;117(1):27\u201356.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"2193_CR2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1053\/j.gastro.2017.09.047","volume":"154","author":"J Tack","year":"2018","unstructured":"Tack J, Pandolfino JE. Pathophysiology of gastroesophageal reflux disease. Gastroenterology. 2018;154(2):277\u201388.","journal-title":"Gastroenterology"},{"key":"2193_CR3","volume-title":"Geriatric gastroenterology","author":"A Ravindran","year":"2020","unstructured":"Ravindran A, Iyer PG. Gastroesophageal reflux disease and complications. In: Pitchumoni C, Dharmarajan T, editors. Geriatric gastroenterology. Cham: Springer; 2020."},{"issue":"2","key":"2193_CR4","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1136\/gut.45.2.172","volume":"45","author":"LR Lundell","year":"1999","unstructured":"Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999;45(2):172\u201380.","journal-title":"Gut"},{"issue":"3","key":"2193_CR5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.5056\/jnm15105","volume":"21","author":"R Dickman","year":"2015","unstructured":"Dickman R, Maradey-Romero C, Gingold-Belfer R, et al. Unmet needs in the treatment of gastroesophageal reflux disease. J Neurogastroenterol Motil. 2015;21(3):309\u201319.","journal-title":"J Neurogastroenterol Motil."},{"issue":"5","key":"2193_CR6","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1053\/j.gastro.2019.12.014","volume":"158","author":"SD Delshad","year":"2020","unstructured":"Delshad SD, Almario CV, Chey WD, et al. Prevalence of gastroesophageal reflux disease and proton pump inhibitor-refractory symptoms. Gastroenterology. 2020;158(5):1250-1261e2.","journal-title":"Gastroenterology"},{"issue":"9","key":"2193_CR7","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/j.1365-2036.2005.02643.x","volume":"22","author":"J Labenz","year":"2005","unstructured":"Labenz J, Armstrong D, Lauritsen K, et al. Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study. Aliment Pharmacol Ther. 2005;22(9):803\u201311.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"2193_CR8","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00535-022-01861-z","volume":"57","author":"K Iwakiri","year":"2022","unstructured":"Iwakiri K, Fujiwara Y, Manabe N, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021. J Gastroenterol. 2022;57(4):267\u201385.","journal-title":"J Gastroenterol"},{"issue":"8","key":"2193_CR9","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1136\/gut.33.8.1016","volume":"33","author":"NE Schindlbeck","year":"1992","unstructured":"Schindlbeck NE, Klauser AG, Berghammer G, et al. Three year follow up of patients with gastrooesophageal reflux disease. Gut. 1992;33(8):1016\u20139.","journal-title":"Gut"},{"issue":"7","key":"2193_CR10","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.cgh.2020.03.057","volume":"19","author":"D Patel","year":"2021","unstructured":"Patel D, Fass R, Vaezi M. Untangling nonerosive reflux disease from functional heartburn. Clin Gastroenterol Hepatol. 2021;19(7):1314\u201326.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"2193_CR11","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/phar.2899","volume":"44","author":"S Zou","year":"2024","unstructured":"Zou S, Ouyang M, Cheng Q, et al. Acid-suppressive drugs: a systematic review and network meta-analysis of their nocturnal acid-inhibitory effect. Pharmacotherapy. 2024;44(2):171\u201383.","journal-title":"Pharmacotherapy"},{"issue":"2","key":"2193_CR12","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1124\/jpet.111.185314","volume":"339","author":"JM Shin","year":"2011","unstructured":"Shin JM, Inatomi N, Munson K, et al. Characterization of a novel potassium-competitive acid blocker of the gastric H, K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438). J Pharmacol Exp Ther. 2011;339(2):412\u201320.","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"2193_CR13","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40265-015-0368-z","volume":"75","author":"KP Garnock-Jones","year":"2015","unstructured":"Garnock-Jones KP. Vonoprazan: first global approval. Drugs. 2015;75(4):439\u201343.","journal-title":"Drugs"},{"key":"2193_CR14","unstructured":"U.S. Food and Drug Administration. VOQUEZNA (vonoprazan) tablets, for oral use: US prescribing information; 2024. https:\/\/www.fda.gov. Accessed 17 Apr 2025."},{"issue":"3","key":"2193_CR15","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s40265-023-01991-5","volume":"84","author":"M Shirley","year":"2024","unstructured":"Shirley M. Vonoprazan: a review in Helicobacter pylori infection. Drugs. 2024;84(3):319\u201327.","journal-title":"Drugs"},{"issue":"11\u20132","key":"2193_CR16","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/apt.13414","volume":"42","author":"DR Scott","year":"2015","unstructured":"Scott DR, Munson KB, Marcus EA, et al. The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+ -ATPase. Aliment Pharmacol Ther. 2015;42(11\u20132):1315\u201326.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"2193_CR17","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/psp4.13235","volume":"14","author":"CW Howden","year":"2025","unstructured":"Howden CW, Scarpignato C, Eckhard L, et al. Mathematical model of the relationship between pH holding time and erosive esophagitis healing rates. CPT Pharmacometr Syst Pharmacol. 2025;14(1):28\u201341.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"issue":"7","key":"2193_CR18","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/MCG.0b013e3181dd9c5b","volume":"44","author":"DA Johnson","year":"2010","unstructured":"Johnson DA, Katz PO, Levine D, et al. Prevention of relapse of healed reflux esophagitis is related to the duration of intragastric pH > 4. J Clin Gastroenterol. 2010;44(7):475\u20138.","journal-title":"J Clin Gastroenterol"},{"issue":"7","key":"2193_CR19","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/apt.13121","volume":"41","author":"H Jenkins","year":"2015","unstructured":"Jenkins H, Sakurai Y, Nishimura A, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Alimentary Pharmacol Ther. 2015;41(7):636\u201348.","journal-title":"Alimentary Pharmacol Ther."},{"issue":"6","key":"2193_CR20","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/apt.13325","volume":"42","author":"Y Sakurai","year":"2015","unstructured":"Sakurai Y, Mori Y, Okamoto H, et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects\u2014a randomised open-label cross-over study. Aliment Pharmacol Ther. 2015;42(6):719\u201330.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"2193_CR21","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3164\/jcbn.17-128","volume":"63","author":"K Ohkuma","year":"2018","unstructured":"Ohkuma K, Iida H, Inoh Y, et al. Comparison of the early effects of vonoprazan, lansoprazole and famotidine on intragastric pH: a three-way crossover study. J Clin Biochem Nutr. 2018;63(1):80\u20133.","journal-title":"J Clin Biochem Nutr."},{"issue":"6","key":"2193_CR22","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/apt.13324","volume":"42","author":"L Lundell","year":"2015","unstructured":"Lundell L, Vieth M, Gibson F, et al. Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Aliment Pharmacol Ther. 2015;42(6):649\u201363.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"2193_CR23","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/cpdd.1009","volume":"11","author":"DJ Mulford","year":"2022","unstructured":"Mulford DJ, Leifke E, Hibberd M, et al. The effect of food on the pharmacokinetics of the potassium-competitive acid blocker vonoprazan. Clin Pharmacol Drug Dev. 2022;11(2):278\u201384.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"12","key":"2193_CR24","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/00498254.2016.1203505","volume":"47","author":"H Yamasaki","year":"2017","unstructured":"Yamasaki H, Kawaguchi N, Nonaka M, et al. In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker. Xenobiotica. 2017;47(12):1027\u201334.","journal-title":"Xenobiotica"},{"issue":"6","key":"2193_CR25","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/jcph.2019","volume":"62","author":"C Scarpignato","year":"2022","unstructured":"Scarpignato C, Leifke E, Smith N, et al. A population pharmacokinetic model of vonoprazan: evaluating the effects of race, disease status, and other covariates on exposure. J Clin Pharmacol. 2022;62(6):801\u201311.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"2193_CR26","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40261-016-0488-6","volume":"37","author":"H Jenkins","year":"2017","unstructured":"Jenkins H, Jenkins R, Patat A. Effect of multiple oral doses of the potent CYP3A4 inhibitor clarithromycin on the pharmacokinetics of a single oral dose of vonoprazan: a phase I, open-label, sequential design study. Clin Drug Investig. 2017;37(3):311\u20136.","journal-title":"Clin Drug Investig"},{"issue":"6","key":"2193_CR27","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/apt.13331","volume":"42","author":"K Ashida","year":"2015","unstructured":"Ashida K, Sakurai Y, Nishimura A, et al. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Aliment Pharmacol Ther. 2015;42(6):685\u201395.","journal-title":"Aliment Pharmacol Ther"},{"issue":"14","key":"2193_CR28","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3748\/wjg.v24.i14.1550","volume":"24","author":"K Ashida","year":"2018","unstructured":"Ashida K, Iwakiri K, Hiramatsu N, et al. Maintenance for healed erosive esophagitis: phase III comparison of vonoprazan with lansoprazole. World J Gastroenterol. 2018;24(14):1550\u201361.","journal-title":"World J Gastroenterol"},{"issue":"5","key":"2193_CR29","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.cgh.2024.08.004","volume":"23","author":"N Uemura","year":"2025","unstructured":"Uemura N, Kinoshita Y, Haruma K, et al. Vonoprazan as a long-term maintenance treatment for erosive esophagitis: VISION, a 5-year, randomized, open-label study. Clin Gastroenterol Hepatol. 2025;23(5):748\u201357.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2193_CR30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.curtheres.2016.12.001","volume":"81\u201382","author":"Y Kinoshita","year":"2016","unstructured":"Kinoshita Y, Sakurai Y, Shiino M, et al. Evaluation of the efficacy and safety of vonoprazan in patients with nonerosive gastroesophageal reflux disease: a phase III, randomized, double-blind, placebo-controlled, multicenter study. Curr Ther Res Clin Exp. 2016;81\u201382:1\u20137.","journal-title":"Curr Ther Res Clin Exp"},{"issue":"11","key":"2193_CR31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14309\/ctg.0000000000000101","volume":"10","author":"Y Kinoshita","year":"2019","unstructured":"Kinoshita Y, Sakurai Y, Takabayashi N, et al. Efficacy and safety of vonoprazan in patients with nonerosive gastroesophageal reflux disease: a randomized, placebo-controlled, phase 3 study. Clin Transl Gastroenterol. 2019;10(11):1\u20139.","journal-title":"Clin Transl Gastroenterol"},{"issue":"1","key":"2193_CR32","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1053\/j.gastro.2022.09.041","volume":"164","author":"L Laine","year":"2023","unstructured":"Laine L, DeVault K, Katz P, et al. Vonoprazan versus lansoprazole for healing and maintenance of healing of erosive esophagitis: a randomized trial. Gastroenterology. 2023;164(1):61\u201371.","journal-title":"Gastroenterology"},{"issue":"11","key":"2193_CR33","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.cgh.2024.05.004","volume":"22","author":"L Laine","year":"2024","unstructured":"Laine L, Spechler S, Yadlapati R, et al. Vonoprazan is efficacious for treatment of heartburn in non-erosive reflux disease: a randomized trial. Clin Gastroenterol Hepatol. 2024;22(11):2211-20.e10.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"2193_CR34","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.cgh.2009.05.015","volume":"7","author":"RM Genta","year":"2009","unstructured":"Genta RM, Schuler CM, Robiou CI, et al. No association between gastric fundic gland polyps and gastrointestinal neoplasia in a study of over 100,000 patients. Clin Gastroenterol Hepatol. 2009;7(8):849\u201354.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"2193_CR35","doi-asserted-by":"crossref","first-page":"453","DOI":"10.5056\/jnm21077","volume":"27","author":"HK Jung","year":"2021","unstructured":"Jung HK, Tae CH, Song KH, et al. 2020 Seoul consensus on the diagnosis and management of gastroesophageal reflux disease. J Neurogastroenterol Motil. 2021;27(4):453\u201381.","journal-title":"J Neurogastroenterol Motil."},{"issue":"1","key":"2193_CR36","first-page":"121","volume":"89","author":"MA Valdovinos Diaz","year":"2024","unstructured":"Valdovinos Diaz MA, Amieva-Balmori M, Carmona-Sanchez R, et al. Good clinical practice recommendations for the diagnosis and treatment of gastroesophageal reflux disease. An expert review from the Asociacion Mexicana de Gastroenterologia. Rev Gastroenterol Mex (Engl Ed). 2024;89(1):121\u201343.","journal-title":"Rev Gastroenterol Mex (Engl Ed)"},{"issue":"6","key":"2193_CR37","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/1756283X17705329","volume":"10","author":"K Iwakiri","year":"2017","unstructured":"Iwakiri K, Sakurai Y, Shiino M, et al. A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis. Therap Adv Gastroenterol. 2017;10(6):439\u201351.","journal-title":"Therap Adv Gastroenterol"},{"issue":"4","key":"2193_CR38","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s12664-023-01384-2","volume":"42","author":"S Chandan","year":"2023","unstructured":"Chandan S, Deliwala S, Mohan BP, et al. Vonoprazan versus lansoprazole in erosive esophagitis\u2014a systematic review and meta-analysis of randomized controlled trials. Indian J Gastroenterol. 2023;42(4):475\u201384.","journal-title":"Indian J Gastroenterol"},{"issue":"3","key":"2193_CR39","first-page":"183","volume":"17","author":"D Chinzon","year":"2022","unstructured":"Chinzon D, Moraes-Filho JPP, Domingues G, et al. Vonoprazan in the management of erosive oesophagitis and peptic ulcer-induced medication: a systematic review. Prz Gastroenterol. 2022;17(3):183\u20139.","journal-title":"Prz Gastroenterol"},{"issue":"6","key":"2193_CR40","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/MCG.0000000000001707","volume":"56","author":"T Oshima","year":"2022","unstructured":"Oshima T, Igarashi A, Nakano H, et al. Network meta-analysis comparing vonoprazan and proton pump inhibitors for heartburn symptoms in erosive esophagitis. J Clin Gastroenterol. 2022;56(6):493\u2013504.","journal-title":"J Clin Gastroenterol"},{"issue":"5","key":"2193_CR41","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/jgh.16475","volume":"39","author":"DM Simadibrata","year":"2024","unstructured":"Simadibrata DM, Lesmana E, Fass R. A systematic review and meta-analysis of the efficacy of vonoprazan for proton pump inhibitor-resistant gastroesophageal reflux disease. J Gastroenterol Hepatol. 2024;39(5):796\u2013805.","journal-title":"J Gastroenterol Hepatol"},{"issue":"7","key":"2193_CR42","volume":"16","author":"DE Agago","year":"2024","unstructured":"Agago DE, Hanif N, Ajay Kumar AS, et al. Comparison of potassium-competitive acid blockers and proton pump inhibitors in patients with gastroesophageal reflux disease: a systematic review and meta-analysis of randomized controlled trials. Cureus. 2024;16(7): e65141.","journal-title":"Cureus"},{"issue":"6","key":"2193_CR43","doi-asserted-by":"crossref","first-page":"102373","DOI":"10.1016\/j.clinre.2024.102373","volume":"48","author":"S Bandyopadhyay","year":"2024","unstructured":"Bandyopadhyay S, Verma P, Samajdar SS, et al. Vonoprazan causes symptomatic improvement in non-erosive gastroesophageal reflux disease: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2024;48(6):102373.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"3","key":"2193_CR44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jgh3.13053","volume":"8","author":"DM Simadibrata","year":"2024","unstructured":"Simadibrata DM, Lesmana E, Pratama MIA, et al. A systematic review with meta-analysis: efficacy and safety of potassium-competitive acid blocker compared with proton pump inhibitor in the maintenance of healed erosive esophagitis. JGH Open. 2024;8(3):1\u20138.","journal-title":"JGH Open"},{"issue":"5","key":"2193_CR45","doi-asserted-by":"crossref","first-page":"803","DOI":"10.14309\/ajg.0000000000002714","volume":"119","author":"Q Zhuang","year":"2024","unstructured":"Zhuang Q, Chen S, Zhou X, et al. Comparative efficacy of P-CAB vs proton pump inhibitors for grade C\/D esophagitis: a systematic review and network meta-analysis. Am J Gastroenterol. 2024;119(5):803\u201313.","journal-title":"Am J Gastroenterol"},{"key":"2193_CR46","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X17745776","author":"K Sugano","year":"2018","unstructured":"Sugano K. Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date. Therap Adv Gastroenterol. 2018. https:\/\/doi.org\/10.1177\/1756283X17745776.","journal-title":"Therap Adv Gastroenterol"},{"issue":"3","key":"2193_CR47","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1159\/000506152","volume":"102","author":"Y Abe","year":"2021","unstructured":"Abe Y, Koike T, Saito M, et al. The ameliorating effect of switching to vonoprazan: a novel potassium-competitive acid blocker in patients with proton pump inhibitor refractory non-erosive reflux disease. Digestion. 2021;102(3):480\u20138.","journal-title":"Digestion"},{"issue":"2","key":"2193_CR48","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000497775","volume":"101","author":"J Akiyama","year":"2020","unstructured":"Akiyama J, Hosaka H, Kuribayashi S, et al. Efficacy of vonoprazan, a novel potassium-competitive acid blocker, in patients with proton pump inhibitor-refractory acid reflux. Digestion. 2020;101(2):174\u201383.","journal-title":"Digestion"},{"issue":"2","key":"2193_CR49","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1159\/000456072","volume":"95","author":"S Hoshino","year":"2017","unstructured":"Hoshino S, Kawami N, Takenouchi N, et al. Efficacy of vonoprazan for proton pump inhibitor-resistant reflux esophagitis. Digestion. 2017;95(2):156\u201361.","journal-title":"Digestion"},{"issue":"17","key":"2193_CR50","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.2169\/internalmedicine.0492-17","volume":"57","author":"R Niikura","year":"2018","unstructured":"Niikura R, Yamada A, Hirata Y, et al. Efficacy of vonoprazan for gastroesophageal reflux symptoms in patients with proton pump inhibitor-resistant non-erosive reflux disease. Intern Med. 2018;57(17):2443\u201350.","journal-title":"Intern Med"},{"issue":"3","key":"2193_CR51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/br.2021.1408","volume":"14","author":"S Shinozaki","year":"2021","unstructured":"Shinozaki S, Osawa H, Hayashi Y, et al. Long-term vonoprazan therapy is effective for controlling symptomatic proton pump inhibitor-resistant gastroesophageal reflux disease. Biomed Rep. 2021;14(3):1\u20137.","journal-title":"Biomed Rep"},{"issue":"4","key":"2193_CR52","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10388-019-00676-x","volume":"16","author":"T Tanabe","year":"2019","unstructured":"Tanabe T, Hoshino S, Kawami N, et al. Efficacy of long-term maintenance therapy with 10-mg vonoprazan for proton pump inhibitor-resistant reflux esophagitis. Esophagus. 2019;16(4):377\u201381.","journal-title":"Esophagus"},{"issue":"47","key":"2193_CR53","first-page":"1","volume":"101","author":"S Yang","year":"2022","unstructured":"Yang S, Deng W, Xie Z, et al. Efficacy and safety of proton pump inhibitors versus vonoprazan in treatment of erosive esophagitis: a PRISMA-compliant systematic review and network meta-analysis. Medicine (Baltimore). 2022;101(47):1\u20138.","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"2193_CR54","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/apt.18458","volume":"61","author":"CW Howden","year":"2025","unstructured":"Howden CW, Katz P, DeVault KR, et al. Integrated analysis of vonoprazan safety for symptomatic gastro-oesophageal reflux disease or erosive oesophagitis. Aliment Pharmacol Ther. 2025;61(5):835\u201351.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"2193_CR55","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.cgh.2024.01.049","volume":"23","author":"ED Shah","year":"2025","unstructured":"Shah ED, Curley MA, Patel A, et al. Heartburn relief is the major unmet need for drug development in gastroesophageal reflux disease: threshold value analysis. Clin Gastroenterol Hepatol. 2025;23(2):263\u201371.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"17","key":"2193_CR56","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.2169\/internalmedicine.2535-18","volume":"58","author":"Y Habu","year":"2019","unstructured":"Habu Y. Vonoprazan versus lansoprazole for the initial treatment of reflux esophagitis: a cost-effectiveness analysis in Japan. Intern Med. 2019;58(17):2427\u201333.","journal-title":"Intern Med"},{"issue":"8","key":"2193_CR57","first-page":"1","volume":"10","author":"Z Wang","year":"2022","unstructured":"Wang Z, Sun R, Sheng Y, et al. Cost-effectiveness analysis of vonoprazan versus proton pump inhibitors in the treatment of reflux esophagitis in China. Ann Transl Med. 2022;10(8):1\u201310.","journal-title":"Ann Transl Med"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02193-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02193-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02193-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T15:55:37Z","timestamp":1750694137000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02193-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":57,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["2193"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02193-x","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]},"assertion":[{"value":"17 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Simon Fung is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability"}}]}}